Journal of European Economic History journal thumbnail
Volume:7, Issue: 3
Citations
65 Views
76 Downloads
Share this article
Useful Links
  • Frequently Asked Questions (FAQs)
Journal of European Economic History
2026, Volume:7, Issue: 3 : 543-570 doi: 10.61336/JEEH/23-3-37
Research Article
Biosimilars at the Intersection of Pharmacy Ethics and Regulatory Governance: A Comparative Review of Patient Safety, Equitable Access, Interchangeability, and Accountability in India and the United Kingdom
 ,
 ,
 ,
 ,
1
Assistant Professor, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, U.P., India;
2
Associate Professor, School of Pharmacy & Research, Dev Bhoomi Uttarakhand University, Naugaon, Dehradun, India
3
Associate Professor, IITM COLLEGE OF PHARMACY, Murthal, Sonipat
4
Assistant Professor, Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, UP, India; 0009-0000-9158-9356
5
Assistant Professor, Department of Law and Legal Studies, Teerthanker Mahaveer College of Law and Legal Studies, Teerthanker Mahaveer University, Moradabad, UP, India, PIN-244001
Received
Sept. 7, 2026
Revised
Sept. 11, 2026
Accepted
Sept. 23, 2026
Published
Oct. 3, 2026
Abstract

Biosimilar medicines have become increasingly important in contemporary pharmaceutical care because they can expand access to complex biological therapies while potentially reducing treatment expenditure. Unlike conventional generic medicines, biosimilars are not molecularly identical copies of their reference biological products because biological medicines are inherently complex and are manufactured using living systems. Consequently, their development and clinical use require a regulatory framework based on comprehensive analytical, functional, non-clinical, and, where appropriate, clinical comparability. The ethical governance of biosimilars therefore extends beyond demonstration of pharmaceutical quality and clinical similarity to encompass patient safety, equitable access, informed decision-making, interchangeability, pharmacovigilance, professional accountability, and responsible allocation of healthcare resources. This review examines biosimilar governance from a pharmacy ethics perspective, with particular emphasis on India and the United Kingdom. The Indian framework has evolved through the Guidelines on Similar Biologics issued by the Department of Biotechnology and the Central Drugs Standard Control Organization, whereas the United Kingdom regulates biosimilars through the Medicines and Healthcare products Regulatory Agency and associated national healthcare policies. Both systems emphasize quality, safety, efficacy, traceability, and post-marketing surveillance, but differences exist in regulatory organization, interchangeability, pharmacy-level substitution, patient involvement in switching decisions, and implementation of pharmacovigilance. In the UK, an authorized biosimilar is considered interchangeable with its reference product from a regulatory perspective, while pharmacy-level substitution without prescriber involvement is not permitted. In India, regulatory approval establishes biosimilarity, but the practical framework for interchangeability and substitution remains less explicitly standardized across routine pharmacy practice. From an ethical perspective, responsible biosimilar governance requires balancing individual patient interests with the collective objective of improving access to affordable biological therapies. Pharmacists have important responsibilities in product identification, patient education, adverse-event reporting, medication safety, and communication regarding switching. A patient-centred approach should avoid both unjustified resistance to biosimilars and inappropriate substitution driven solely by cost. Greater regulatory harmonization, transparent pharmacovigilance, standardized product traceability, pharmacist education, and meaningful patient participation may strengthen ethical biosimilar implementation in India and the United Kingdom.

Keywords
License
Copyright (c) Journal of European Economic History
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
J Euro Eco His open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Recommended Articles
Research Article Open Access
Ready or Not: Generation Z’s Defining Traits and Struggles Entering the Workforce
2026, Volume:7, Issue: 3 : 1250-1263
DOI: 10.61336/JEEH/23-3-80
Research Article Open Access
Digital Sovereignty and Data Colonialism: Governance, Power, and Economic Control in Platform-Dominated Markets
2026, Volume:7, Issue: 3 : 1224-1238
DOI: 10.61336/JEEH/23-3-78
Research Article Open Access
Expectation – Reality Gap in Retailers’ Perceptions: A Study of Product Performance and Retailer Satisfaction
2026, Volume:7, Issue: 3 : 1149-1164
DOI: 10.61336/JEEH/23-3-74
Research Article Open Access
Barriers to Girls’ School Enrollment: A Survey-Based Analysis
2026, Volume:7, Issue: 3 : 1239-1249
DOI: 10.61336/JEEH/23-3-79
© Copyright @Banco di Roma, Unless it otherwise mention
Email: support@unicredit-capitalia.eu